Your browser doesn't support javascript.
loading
Therapeutic efficacy of rituximab combined with cyclosporin A on B-cell dysregulation in chronic graft-versus-host disease.
Fu, Xiang-Jun; Meng, Can; Guo, Li; Lin, Li-E.
Afiliação
  • Fu XJ; Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, NO.19 Xiuhua Road, Xiuying District, Haikou, 570311, Hainan Province, China.
  • Meng C; Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, NO.19 Xiuhua Road, Xiuying District, Haikou, 570311, Hainan Province, China.
  • Guo L; Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, NO.19 Xiuhua Road, Xiuying District, Haikou, 570311, Hainan Province, China.
  • Lin LE; Department of Hematology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, NO.19 Xiuhua Road, Xiuying District, Haikou, 570311, Hainan Province, China. linlielln@126.com.
Clin Transl Oncol ; 2024 Sep 04.
Article em En | MEDLINE | ID: mdl-39231914
ABSTRACT

OBJECTIVE:

Chronic graft-versus-host disease (cGVHD) is a significant complication following allogenic hematopoietic stem cell transplantation, often necessitating therapeutic interventions such as rituximab (RTX) and cyclosporin A (CsA). This study aims to elucidate the mechanisms by which RTX and CsA jointly address B-cell dysregulation in cGVHD, providing a theoretical foundation and scientific rationale for the treatment and prognostic evaluation of this condition.

METHODS:

A total of 30 cGVHD mouse models were established by subjecting recipient mice to total body irradiation followed by injection of a mixed suspension of bone marrow cells and splenocytes from donor mice. From Day 2 to Day 29 post-model establishment, the mice received subcutaneous administration of RTX and CsA. Throughout the study, body weight, clinical cGVHD scores, and survival rates were monitored. Blood samples were collected via the orbital venous plexus. Serum levels of B-cell activating factor (BAFF) and pro-inflammatory factors were measured using enzyme-linked immunosorbent assay (ELISA), and the ratio of regulatory B cells (Bregs) in the blood sample was assessed via flow cytometry.

RESULTS:

Mice with cGVHD exhibited a 14.5% decrease in body weight, elevated clinical scores, and more severe symptoms compared to the control group. Notably, all mice in both the cGVHD and control groups survived until the conclusion of the study. Induction of cGVHD resulted in B-cell dysregulation, evidenced by elevated serum BAFF levels and a decreased proportion of Bregs. However, treatment with RTX combined with CsA ameliorated B-cell dysregulation and significantly reduced serum levels of pro-inflammatory factors in cGVHD mice, with decreases of 39.78% in TNF-α and 37.89% in IL-6.

CONCLUSION:

The combination of RTX and CsA effectively mitigates B-cell dysregulation in cGVHD, thereby reducing the severity and progression of the disease.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Itália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Itália